Cancer cell invasion of extracellular matrix (ECM) is essential for dissemination of cancer cells and metastasis. In this study, we have investigated the role of mitogen inducible gene-2 (Mig-2, also known as kindlin-2), a focal adhesion protein whose expression is altered in several types of human cancers, in mesenchymal cancer cell invasion. Mig-2 is abundantly expressed in SK-LMS-1 leiomyosarcoma cells. The level of Mig-2, however, is considerably lower in more invasive HT-1080 fibrosarcoma cells. Overexpression of Mig-2 in HT-1080 and SK-LMS-1 cells substantially reduced their ability to invade ECM in an in vitro Matrigel invasion assay. Conversely, knockdown of Mig-2 markedly increased the invasiveness of these cells. Consistent with a suppressive role in mesenchymal cancer cell invasion, Mig-2 inhibits urokinase-type plasminogen activator (uPA) secretion and pericellular proteolysis. Overexpression of Mig-2 increased uPA accumulation at the intracellular face of cell-ECM adhesions and reduced the level of secreted uPA. Conversely, knockdown of Mig-2 reduced uPA accumulation at the intracellular face of cell-ECM adhesions and increased uPA secretion. Our results reveal an important role of Mig-2 in suppression of mesenchymal cancer cell invasion and shed new light on how altered Mig-2 expression could influence cancer cell invasion. (Mol Cancer Res 2008;6(5):715 -24) 
Introduction
Increased invasiveness is a hallmark of metastatic cancer cells. Recent studies suggest that cancer cells can invade extracellular matrix (ECM) through different mechanisms (1) (2) (3) . Many cancer cells can invade through ECM with an elongated morphology resembling that of mesenchymal cells (hence, termed as mesenchymal invasion). The mesenchymal mode of invasion requires pericellular proteolytic degradation of ECM (2) . Consistent with a role of proteases in this mode of invasion, elevated expression or secretion of ECM degrading proteases, such as urokinase-type plasminogen activator (uPA) has been closely associated with increased ECM invasion and poor prognosis of several types of tumors (4) (5) (6) (7) . However, mesenchymal invasion is not the only mechanism through which cancer cells can migrate through ECM. Some cancer cells can invade ECM with a rounded morphology resembling that of amoebas. The amoeboid mode of invasion does not require proteolytic degradation of ECM. Instead, it is highly dependent on Rho/ROCK signaling (1) . The ability of cancer cells to invade ECM through two distinct modes represents a major obstacle for therapeutic intervention of cancer cell invasion and metastasis (8) , as different mechanisms are involved in regulation of these two modes of invasion. Thus, to improve the efficacy of therapeutic control of cancer cell invasion and metastasis, it is important to identify proteins that regulate different modes of cancer cell invasion and determine the molecular mechanisms whereby they function.
Integrins and associated cell-ECM adhesion proteins play important roles in regulation of cancer cell invasion (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Mitogen inducible gene-2 (Mig-2, also known as kindlin-2) is an integrin-binding scaffolding protein that is concentrated at the intracellular face of cell-ECM adhesions, where it links integrins to the actin cytoskeleton (20) (21) (22) (23) . Recent studies have shown that Mig-2 is highly expressed in aggressive human TMX2-28 breast cancer cells (24) . Interestingly, small interfering RNA (siRNA) -mediated suppression of Mig-2 expression significantly reduced the invasion of TMX2-28 cells through Matrigel, indicating that Mig-2 plays a positive role in promoting the invasion of TMX2-28 breast cancer cells (24) . Immunohistochemical analyses of normal and cancerous breast tissues, however, showed that, whereas all (21 cases) of normal human breast tissues that were analyzed express Mig-2, 50% (17 of 34 cases that were analyzed) of human breast cancer tissues lost Mig-2 expression (24) . On the other hand, among the 17 cases of Mig-2 -positive breast cancer, Mig-2 was overexpressed in 10 of them (24) . Thus, both up-regulation and down-regulation of Mig-2 expression were found in breast cancer. These results suggest that alterations (either increase or decrease) of the Mig-2 level could potentially contribute to malignant behaviors. In a separate study, Kato et al. have shown that Mig-2 expression in uterine leiomyosarcoma cells, which adopt a mesenchymal morphology, is significantly lower than that of the less invasive uterine leiomyoma cells (25) . This raised an interesting possibility that Mig-2 may play a role in regulation of mesenchymal cancer cell invasion. To test this possibility, we have up-regulated and down-regulated Mig-2 expression in SK-LMS-1 leiomyosarcoma cells and HT-1080 fibrosarcoma cells and determined the functional consequences.
Our results reveal an important role of Mig-2 in suppression of mesenchymal cancer cell invasion and shed new light on how altered Mig-2 expression could participate in regulation of cancer cell invasion.
Results and Discussion
Overexpression of Mig-2 Suppresses SK-LMS-1 Leiomyosarcoma Cell Invasion
To investigate the role of Mig-2 in SK-LMS-1 leiomyosarcoma cell invasion, we first sought to overexpress Mig-2 in these cells. To do this, we generated an adenoviral expressing vector encoding Mig-2 and infected SK-LMS-1 cells with the Mig-2 adenoviral vector and a control adenoviral vector encoding h-galactosidase, respectively. Western blotting analyses with a monoclonal anti -Mig-2 antibody showed that the level of Mig-2 was increased in SK-LMS-1 cells infected with the Mig-2 adenovirus (Fig. 1A , compare lane 2 with lane 1) but not in those infected with the control h-galactosidase adenovirus (Fig. 1A , compare lane 3 with lane 1). The increased amount of Mig-2 in lane 2 was not caused by overloading of the sample, as a similar amount of actin was detected in all three lanes when the samples were probed with an anti-actin antibody (Fig. 1B) . To assess cell invasion, we seeded the Mig-2 overexpressing leiomyosarcoma cells and the control cells, respectively, in Matrigel invasion chambers.
SK-LMS-1 leiomyosarcoma cells exhibited an elongated morphology resembling that of mesenchymal cells (Fig. 1C  and D) . Importantly, the number of Mig-2 overexpressing leiomyosarcoma cells invaded through the Matrigel was reduced by >40% when compared with that of the control cells (Fig. 1C-E) . These results provide initial evidence for a suppressive role of Mig-2 in leiomyosarcoma cell invasion.
Knockdown of Mig-2 Enhances SK-LMS-1 Leiomyosarcoma Cell Invasion
To further investigate the role of Mig-2 in regulation of leiomyosarcoma cell invasion, we suppressed Mig-2 expression in SK-LMS-1 cells. To do this, we transfected the cells with an siRNA that targets Mig-2 (21) and an irrelevant RNA as a control, respectively. Western blotting analyses showed that Mig-2 expression was substantially reduced in the Mig-2 siRNA transfectants ( Fig. 2A , compare lane 2 with lane 1) but not the control transfectants ( Fig. 2A , compare lane 3 with lane 1). Equal loading was confirmed by probing the same samples with an anti-actin antibody (Fig. 2B ). Analyses of cell invasion showed that suppression of Mig-2 expression markedly increased the number of the leiomyosarcoma cells invaded through the Matrigel (Fig. 2C-E) . These results are highly consistent with the results obtained with overexpression of Mig-2. Collectively, these results strongly suggest that Mig-2 functions as a negative regulator of leiomyosarcoma cell invasion.
Mig-2 Suppresses HT-1080 Fibrosarcoma Cell Invasion
To further test the role of Mig-2 in mesenchymal cancer cell invasion, we altered the expression of Mig-2 in HT-1080 fibrosarcoma cells, which also invade ECM through the mesenchymal mode (2, 8) . HT-1080 fibrosarcoma cells expressed a lower level of Mig-2 than SK-LMS-1 cells (Fig. 3A, compare lanes 1 and 2) . Consistent with a role of Mig-2 in suppression of mesenchymal invasion, a much larger number of HT-1080 cells invaded through Matrigel (Fig. 3E and F) comparing with that of SK-LMS-1 cells (Fig. 3D and F) under identical experimental conditions. To directly test whether the low level of Mig-2 in HT-1080 cells contributed to the high invasiveness of HT-1080 cells, we overexpressed Mig-2 in HT-1080 cells. To do this, HT-1080 cells were infected with the Mig-2 adenovirus, and the h-galactosidase adenovirus as a control, respectively. Overexpression of Mig-2 in HT-1080 cells infected with the Mig-2 adenovirus, but not those infected with the control adenovirus, was confirmed by Western blotting (Fig. 4A and B) . Noticeably, Mig-2 overexpressing HT-1080 cells were substantially less invasive than the control HT-1080 cells (Fig. 4C-E) . Thus, increased expression of Mig-2 effectively reduces the invasiveness of HT-1080 fibrosarcoma cells.
To further test the role of Mig-2 in suppression of HT-1080 cell invasion, we transfected the cells with Mig-2 siRNA and control RNA, respectively. Western blotting analyses showed that the level of Mig-2 was modestly reduced in the Mig-2 siRNA transfectants ( Fig. 5A and B, compare lane 2 with lanes 1 and 3) . Despite the modest reduction of the Mig-2 level in the Mig-2 siRNA transfectants, cell invasiveness was significantly increased (Fig. 5C-E) . These results confirm that Mig-2 plays a suppressive role in mesenchymal cancer cell invasion.
Mig-2 Negatively Regulates the Level of Secreted uPA
Mesenchymal invasion depends on proteolytic degradation of ECM (2) . It has been well established that uPA plays an important role in proteolytic degradation of ECM and tumor cell invasion (4-7). During our investigation, we found that the level of secreted uPA in the moderately invasive SK-LMS-1 cells (Fig. 3C, lane 1) was markedly lower than that of the more invasive HT-1080 cells (Fig. 3C, compare lanes 1 and 2) . Because SK-LMS-1 cells express a higher level of Mig-2 than HT-1080 cells (Fig. 3A, compare lanes 1 and 2) , this raised an interesting possibility that Mig-2 may regulate the level of uPA. To test this possibility, we transfected SK-LMS-1 cells with the Mig-2 siRNA and the control RNA, respectively. Consistent with the previous results ( Fig. 2A) , transfection of SK-LMS-1 cells with Mig-2 siRNA substantially reduced the level of Mig-2 (Fig. 6A , compare lane 2 with lane 1). Equal loading was confirmed by probing the same samples with an anti-actin antibody (Fig. 6B) . Knockdown of Mig-2 did not significantly alter the cellular level of uPA (Fig. 6C, lanes 1 and 2) . SK-LMS-1 cells normally secreted a relatively low level of uPA that was barely detectable by Western blotting (Fig. 6C, lane 3) . Notably, knockdown of Mig-2 significantly increased the level of secreted uPA (Fig. 6C , compare lane 4 with lane 3). Coomassie blue staining detected a similar amount of albumin in both lanes (Fig. 6D) , confirming equal loading of the samples.
To confirm a role of Mig-2 in this process, we analyzed the effect of Mig-2 overexpression on the level of secreted uPA. To do this, we infected SK-LMS-1 cells with the Mig-2 adenovirus or the h-galactosidase adenovirus as a control. Overexpression of Mig-2 in the Mig-2 adenoviral infected SK-LMS-1 cells, but not the h-galactosidase adenoviral-infected cells or parental SK-LMS-1 cells, was confirmed by Western blotting ( Fig. 7A and B) . The cellular level of uPA in the Mig-2 adenoviral infected SK-LMS-1 cells was similar to that of the control cells (Fig. 7C ), suggesting that overexpression of Mig-2 does not significantly alter the level of cellular uPA. Because SK-LMS-1 cells secret a very low level of uPA that is barely detectable by Western blotting (Fig. 6C , lane 3 ), we concentrated the conditioned media from the Mig-2 overexpressing cells or the control cells. Western blotting analyses showed that the level of uPA secreted by the Mig-2 overexpressing cells was significantly lower than that of the control cells (Fig. 7D , compare lane 2 with lanes 1 and 3). A similar amount of albumin was detected in all three lanes (Fig. 7E ), confirming equal concentrating and loading of the samples. Taken together, these results show that overexpression of Mig-2 reduces, whereas knockdown of Mig-2 increases, the level of secreted uPA.
Mig-2 Regulates Subcellular Distribution of uPA
How does Mig-2 regulate the level of secreted uPA? To begin to address this question, we analyzed the subcellular distribution of uPA and Mig-2. To do this, we transfected SK-LMS-1 cells with a DNA vector encoding Mig-2 and a control vector lacking Mig-2 sequence, respectively. The cells were permeabilized with 0.1% Triton X-100 and then dually stained with rabbit anti-uPA antibody and mouse monoclonal anti -Mig-2 antibody. Consistent with previous studies (26) (27) (28) (29) (30) , a fraction of uPA was detected at cell-ECM adhesions (Fig. 8C) , where Mig-2 was concentrated (Fig. 8A) . The level of cell-ECM adhesion uPA staining was noticeably increased in Mig-2 overexpressing cells ( Fig. 8B and D) , suggesting that an elevation of the Mig-2 level increases the accumulation of uPA at the adhesion sites. To confirm this, we immunofluorescently stained the Mig-2 or h-galactosidase adenoviral-infected SK-LMS-1 cells with the anti-uPA antibody (the adenoviralinfected cells was identified by the presence of GFP, which was encoded by the adenoviral expression vectors under a promoter separated from that of Mig-2 or h-galactosidase). Under the experimental conditions used, f80% to 90% of the Mig-2 or h-galactosidase adenoviral infected cells were GFP-positive. Immunofluorescent staining of the adenoviral infected cells showed that many Mig-2 adenoviral infected cells exhibited strong cell-ECM adhesion uPA staining ( Fig. 8F shows a representative image of the Mig-2 adenoviral infected cells with strong uPA staining at cell-ECM adhesions). Because the intensity of the cell-ECM adhesion uPA staining in a cell population was not uniform, we counted the cells that exhibited strong cell-ECM adhesion uPA staining (Fig. 8G) . In control cells, approximately one third of the cells exhibited weak cell-ECM adhesion uPA staining, one third exhibited strong cell-ECM adhesion uPA staining, and one third exhibited intermediate cell-ECM adhesion uPA staining (Fig. 8E shows an example of the control cells with intermediate uPA staining at cell-ECM adhesions). In Mig-2 overexpressing cells, the percentage of the cells with strong cell-ECM adhesion uPA staining was almost doubled (to >60%; Fig. 8G ). Thus, overexpression of Mig-2 promotes uPA accumulation at cell-ECM adhesions.
To distinguish whether the increased accumulation of uPA is at the extracellular or the intracellular face of cell-ECM adhesions, we immunofluorescently stained the cells without permeabilizing the plasma membrane. Clusters of uPA were detected on the surface of nonpermeabilized cells (Fig. 9A-D) . The cell surface staining of uPA, however, was not increased in Mig-2 overexpressing cells (Fig. 9 , compare A and C with B and D). Consistent with the intracellular localization of Mig-2, no specific Mig-2 staining was detected in nonpermeabilized cells ( Fig. 9E and F) . Taken together, these results suggest that overexpression of Mig-2 increases uPA accumulation at the intracellular face of cell-ECM adhesions.
We next compared the uPA distribution in Mig-2 knockdown cells and the control cells. To do this, we immunofluorescently stained the Mig-2 siRNA transfectants and the control RNA transfectants with mouse monoclonal anti -Mig-2 antibody and rabbit polyclonal anti-uPA antibody under permeabilized condition. The level of Mig-2 in many of the Mig-2 siRNA transfectants was noticeably reduced, albeit it was not eliminated ( Fig. 10A and B) . In control RNA transfectants, approximately one third of the cells exhibited weak uPA staining at cell-ECM adhesions and the remaining two thirds exhibited intermediate to strong levels of uPA staining at cell-ECM adhesions (Fig. 10C shows a representative image of a control cell with an intermediate to strong level of cell-ECM adhesion uPA staining). By contrast, very few cells (<5%) with strong uPA staining at cell-ECM adhesions were found in Mig-2 siRNA transfectants. The majority of Mig-2 siRNA transfectants (>50%) exhibited weak uPA staining at cell-ECM adhesions ( Fig. 10G ; a representative image of a Mig-2 knockdown cell with weak uPA staining at cell-ECM adhesions is shown in Fig. 10D ). Thus, a reduction of the Mig-2 level seems to shift the balance toward less uPA at cell-ECM adhesions. Staining of the cells under nonpermeabilized condition showed that cell surface uPA staining was not noticeably altered by knockdown of Mig-2 ( Fig. 10E and F) .
(MMP-2) and MMP-9, we analyzed the levels of secreted MMP-2 and MMP-9 in response to alteration of Mig-2. Unlike the level of secreted uPA, the levels of secreted MMP-2 and MMP-9 were not significantly altered by overexpression or knockdown of Mig-2.
3 Given a critical role of uPA in cancer invasion and progression (4-7), uPA likely represents a major regulatory target of Mig-2, albeit we cannot completely rule out the possibility that other proteases may also participate in Mig-2 -mediated regulation of mesenchymal invasion.
Mig-2 Inhibits Pericellular Proteolytic Activity of SK-LMS-1 and HT-1080 Cells
We next sought to directly test whether Mig-2 plays a role in regulation of pericellular proteolytic activity, which is critical for mesenchymal cancer cell invasion (2, 8) . Pericellular proteolytic activity can be detected using fluorescently labeled intramolecularly self-quenched substrates. Upon proteolytic degradation, the intramolecular self-quenching is relieved, resulting in increase of florescence. Using BODIPY FL-BSA In parallel control experiments, the cells were infected with h-galactosidase adenovirus. To facilitate in situ analysis of Mig-2 and h-galactosidase adenoviral infected cells (which are GFP positive), BODIPY TR-X BSA (DQ Red BSA), which is identical to DQ Green BSA except that it is red-fluorescently labeled, was used in these experiments. Consistent with previous studies (31), incubation of the control HT-1080 and SK-LMS-1 cells (Fig. 11A and C) with DQ Red BSA for 30 minutes resulted in strong red fluorescence that could be readily detected under fluorescence microscopy ( Fig. 11B and D) . By contrast, much weaker red fluorescence was detected in Mig-2 adenoviral infected HT-1080 (Fig. 11 , compare F with B ) and SK-LMS-1 (Fig. 11 , compare H with D ) cells under identical experimental condition, suggesting that Mig-2 plays an important role in suppression of pericellular proteolytic activity. Invasion through ECM is essential for cancer cell dissemination and metastasis, which is the major course of death in cancer patients. Therapeutic intervention of cancer cell invasion, therefore, represents an important strategy for cancer therapy. However, despite numerous efforts, development of therapeutic approaches that effectively prevent cancer cell invasion has proved to be challenging (reviewed in refs. [32] [33] [34] , which is in part due to incomplete understanding of the molecular mechanisms whereby cancer cells invade ECM. An exciting breakthrough in our understanding of cancer cell invasion came from recent experimental studies showing that cancer cells can invade ECM through two morphologically and molecularly distinct modes (e.g., the mesenchymal and amoeboid modes; refs. 1-3). The plasticity of cancer cell invasion may account for, at least in part, the lack of success in clinical trials with protease inhibitors (8) . Previous studies have shown that mesenchymal and amoeboid invasions are controlled by different signaling mechanisms. For example, mesenchymal invasion requires ECM degrading proteases whereas amoeboid invasion is independent of pericellular proteolytic degradation but instead requires Rho and Rock signaling (1, 2) . In this study, we have analyzed the role of Mig-2 in regulation of mesenchymal cancer cell invasion using an in vitro Matrigel invasion assay and found that it plays an important suppressive role in this process. Consistent with this, we have uncovered a role of Mig-2 in inhibition of uPA secretion and pericellular proteolysis. Whereas Mig-2 clearly suppresses mesenchymal cancer cell invasion, recent studies by Gozgit et al. (24) suggest that Mig-2 plays an opposite role (i.e., promoting) in the invasion of TMX2-28 breast cancer cells. These findings may provide an explanation for the clinical observations that Mig-2 is overexpressed in certain cancer cases (e.g., in a subset of breast cancer cases; ref. 24 ) but downregulated or lost in some other cancer cases (e.g., uterine leiomyosarcoma and certain cases of breast cancer; refs. 24, 25) . Based on these findings, we propose a model in which Mig-2 influences cancer cell invasion in an invasion modedependent fashion. Under conditions that favor the mesenchymal mode of invasion, which is dependent on pericellular proteolytic degradation of ECM, Mig-2 inhibits uPA secretion and pericellular proteolysis and consequently suppresses cancer cell invasion. On the other hand, in cancer cells that invade ECM through a protease-independent mode, the presence of Mig-2 could potentially play a different (and sometime even opposite) role. One prediction of this model is that TMX2-28 breast cancer cells, in which Mig-2 promotes cell invasion (24) , likely invade ECM though a proteaseindependent mode. Consistent with this, TMX2-28 breast cancer cells exhibit a rounded epithelial morphology that is distinct from the more elongated mesenchymal morphology (24) . Clearly, future studies are needed to further test whether TMX2-28 breast cancer cells indeed invade ECM through a protease-independent mode, as predicted by our model. A related issue that remains to be resolved is how Mig-2 promotes protease-independent cancer cell invasion. Sahai and Marshall have shown that the protease-independent amoeboid mode of invasion is enhanced by Rho signaling (1). It is worth noting that Mig-2 interacts with h integrins and promotes focal adhesion formation (20) (21) (22) (23) , a process that is known to involve Rho signaling. Thus, it will be interesting to test in future studies whether Mig-2 promotes the protease-independent cancer cell invasion through regulation of Rho signaling.
Materials and Methods
Cells, Antibodies, and Other Reagents SK-LMS-1 leiomyosarcoma cells and HT-1080 fibrosarcoma cells were from American Type Culture Collection. The cells were cultured in MEM supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 0.1 mmol/L nonessential amino acids, and 1.0 mmol/L sodium pyruvate. Mouse monoclonal anti -Mig-2 antibody 3A3 was generated as previously described using glutathione S-transferase fusion protein of Mig-2 fragment from residue 218 to residue 486 (21) . Rabbit polyclonal anti-uPA antibodies were obtained from American Diagnostic. FITCconjugated goat anti-mouse IgG antibody (minimal crossreaction with human, bovine, rabbit, and swine serum proteins), Rhodamine Red TX -conjugated goat anti-rabbit IgG antibody (minimal cross-reaction with human, mouse, and rat serum proteins) and horseradish peroxidase -conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories. Restriction endonucleases were obtained from New England Biolabs, Inc. Cell culture media were from Sigma-Aldrich or Invitrogen. All other chemicals were from Fisher Scientific or Sigma-Aldrich.
siRNA, DNA Construct, and Transfection
The Mig-2 specific siRNA and the control RNA were previously described (21) . SK-LMS-1 leiomyosarcoma cells and HT-1080 fibrosarcoma cells were transfected with the Mig-2 and the control RNA using Oligofectamine or Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol. The DNA expression vector encoding Mig-2 was generated by inserting full-length human Mig-2 cDNA (including the stop codon) into the EcoRI/KpunI sites of the p3xflag-CMV-14 vector (Sigma). The cells were transfected with the Mig-2 expression vector or a control p3xflag-CMV-14 vector lacking Mig-2 cDNA sequence using Lipofectamine Plus (Invitrogen).
Generation of Adenoviral Mig-2 Expression Vector and Infection
Adenoviral Mig-2 expression vector was generated using the AdEasy system following a previously described protocol (35, 36) . Briefly, full-length human Mig-2 cDNA was cloned into the NotI/XbaI site of the pAdTrack-CMV shuttle vector. The resultant plasmid was linearized with PmeI, purified, and mixed with supercoiled pADEsay-1. The vectors were transferred into E. coli BJ5183 by electroporation using a Bio-Rad Gene Pulser electroporator. Recombinants that were resistant to kanamycin were selected, and recombination was confirmed by PacI digestion. The positive plasmids were then transformed into DH5a by heat shock for large-scale amplification. The plasmid DNA was digested with PacI, ethanol-precipitated, and used to transfect 293 cells with Lipofectamine Plus (Invitrogen). The transfectants were harvested f10 d after transfection. The cells were lysed by three cycles of freezing in a methanol/ dry ice bath and rapid thawing at 37jC, and the lysates containing the recombinant adenovirus were collected. The control adenoviral expressing vector encoding h-galactosidase was kindly provided by Drs. Tong-Chuan He and Bert Vogelstein (Howard Hughes Medical Institute, Johns Hopkins Oncology Center). The adenoviral expressing vectors were used to infect cells as specified in each experiment. The infection efficiency was monitored by the expression of GFP encoded by the viral vectors, and typically, it reached 80% to 90% within 1 d after infection. Overexpression of Mig-2 in the infected cells was confirmed by Western blotting with a monoclonal anti -Mig-2 antibody.
Cell Invasion
Cell invasion was analyzed using Matrigel invasion chambers (Becton Dickinson) following the manufacturer's protocol. Briefly, cells were trypsinized 24 h after RNA transfection or adenoviral infection and washed twice with PBS containing 1 mg/mL bovine serum albumin (BSA). Cells were then suspended in MEM containing 1 mg/mL BSA at densities as specified in each experiment. Equal volume (0.5 mL/chamber) of the cell suspensions were seeded in the Matrigel invasion chambers (Becton Dickinson) that were placed in wells of 24-well culture plates containing 0.75 mL/well of culture medium supplemented with 10% fetal bovine serum. The cells were incubated in a 37jC incubator under a 5% CO 2 -95% air atmosphere for periods of time as specified in each experiment. At the end of the incubation, the noninvaded cells that remained on the upside of the filter were removed. The invaded cells were fixed, stained with hematoxylin, and photographed under an Olympus IX70 microscope equipped with a DVC-1310C Magnafire digital camera (Optronics). The number of invaded cells was quantified by counting cells from five microscopic fields (1.42 mm 2 /field). Cell invasiveness is expressed as the average number of invaded cells per microscopic field.
uPA Secretion
Cells were seeded in MEM supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 0.1 mmol/L nonessential amino acids, and 1.0 mmol/L sodium pyruvate in 35-mm culture dishes and transfected with Mig-2 siRNA or control RNA or infected with adenoviruses, as specified in each experiment. Twenty-four hours after the RNA transfection (or adenoviral infection), cells were switched to serum-free culture medium and then incubated in a 37jC incubator under a 5% CO 2 -95% air atmosphere for 24 h more. At the end of incubation, the culture media were collected and centrifuged at 4,000 rpm for 10 min. Bovine serum albumin was added to the supernatants (to final concentration of 50 Ag/mL) and was used as an internal control for sample concentrating, loading, and transfer. The amount of uPA in the culture supernatants was analyzed by Western blotting with a rabbit anti-uPA antibody (American Diagnostic). In some experiments, proteins in the culture supernatants were first concentrated using Amicon Ultrafree-4 centrifugal filters (Millipore). The samples were then analyzed by Western blotting with the anti-uPA antibody.
Immunofluorescent Staining
Cells (as specified in each experiment) were plated on fibronectin-coated coverslips and cultured in MEM supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 0.1 mmol/L nonessential amino acids, and 1.0 mmol/L sodium pyruvate in a 37jC incubator under a 5% CO 2 -95% air atmosphere for 24 h. The cells were fixed with 4% paraformadehyde and then either permeabilized with 0.1% Triton X-100 in 50 mmol/L Tris-HCl (pH 7.4) containing 150 mmol/L NaCl, 0.2 mg/mL NaN 3 , and 1 mg/mL BSA or rinsed with the Tris buffer in the absence of Triton X-100 (nonpermeabilized condition). The permeabilized and nonpermeabilized cells were stained with rabbit polyclonal antiuPA antibody (4 Ag/mL) and/or mouse monoclonal anti -Mig-2 antibody 3A3 (3 Ag/mL). The primary antibodies were detected with Rhodamine Red TX -conjugated antirabbit IgG and/or FITC-conjugated antimouse IgG secondary antibodies as specified in each experiment.
Pericellular Proteolysis
Pericellular proteolytic activity in live cells was analyzed based on a previously described method (31) . Briefly, 1 mg of DQ Red BSA (Invitrogen), a red fluorescently labeled intramolecular self-quenched protein, was dissolved in 1 mL of water (cell culture grade) and stored at 4jC. The stock solution of DQ Red BSA was diluted with water (final concentration of the working solution, 10 Ag/mL) and used to coat glass coverslips. Cells (as specified in each experiment) were seeded in culture dishes containing DQ Red BSA -coated coverslips and incubated at 37jC. Thirty minutes after seeding, the coverslips containing live cells were observed under a florescence microscopy equipped with GFP (for detection of adenoviral infected cells) and rhodamine (for detection of degraded DQ Red BSA) filters. In control experiments, the cells were plated on BSA-coated coverslips, and no red florescence was detected under otherwise identical experimental conditions (data not shown).
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